What Happened?
Shares of healthcare services company Astrana Health fell 31.9% in the afternoon session after the company reported weak fourth quarter results, its full-year EBITDA guidance missed significantly and its EPS fell short of Wall Street's estimates. On the other hand, Astrana Health blew past analysts' revenue expectations, driven by a nearly twofold increase in Care Partners sales. Looking ahead, the company expects 2025 revenue growth of at least 28%, a significant deceleration from the prior year. Overall, this was a weaker quarter.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Astrana Health? Access our full analysis report here, it’s free.
What The Market Is Telling Us
Astrana Health’s shares are quite volatile and have had 15 moves greater than 5% over the last year. But moves this big are rare even for Astrana Health and indicate this news significantly impacted the market’s perception of the business.
Astrana Health is down 21.6% since the beginning of the year, and at $25.25 per share, it is trading 59.6% below its 52-week high of $62.54 from October 2024. Investors who bought $1,000 worth of Astrana Health’s shares 5 years ago would now be looking at an investment worth $1,445.
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
